| Melanoma Clinical Trials- Recruiting | Phase |
| NCT01227889 A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma |
Phase III |
| NCT00297895 Multicenter Selective Lymphadenectomy Trial II (MSLT-II) |
Phase III |
| NCT00911326 Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma |
Phase III |
| NCT01120275 RO4929097 in Treating Patients With Stage IV Melanoma |
Phase II |
| NCT01266967 A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain |
Phase II |
| NCT00940225 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies |
Phase II |
| NCT01120275 RO4929097 in Treating Patients With Stage IV Melanoma |
Phase II |
| NCT00730639 A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies |
Phase I |
| NCT00730639 A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies |
Phase I |
| NCT00897442 Collecting Tumor Samples From Patients With Gynecological Tumors |
|
| Updated from clinicaltrials.gov on 8/24/2011 |
- About Melanoma
- Research
- Interesting Items
- Clinical Trials
- Ann Arbor, MI – University of Michigan
- Bethesda, MD – National Institutes of Health (NIH)
- Houston, TX – M D Anderson Medical Center
- Pittsburgh, PA– University of Pittsburgh Medical Center
- Santa Monica, CA – John Wayne Cancer Institute and the Los Angeles Clinic and Research Institute
- Cincinnati and Dayton, Ohio
- Kentucky
- Indiana
- Participating in a Clinical Trial
- Professional Meetings
- Continuing Medical Education Programs
- Programs
- Get Involved
- Events
- Donate
- Media Center
- About Us
- Contact Us
